ClinicalTrials.gg
RecruitingNCT07691450Updated Oct 30, 2026

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

A Phase 1 interventional study of Azacitidine and Belinostat in Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma and Recurrent Follicular Helper T-Cell Lymphoma, sponsored by City of Hope Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Lymphoma, Large-Cell, Anaplastic by City of Hope Medical Center — 1 open to participants now, 5 under way, none of them phase 3. Lymphoma, Large-Cell, Anaplastic · City of Hope Medical Center.

Planned enrollment
4th of 14
40 · median 22
Started
2027
the only one that year
Phase 1
6 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Lymphoma, Large-Cell, Anaplastic by City of Hope Medical Center, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 1, and was the 15th registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

1 of the 15 studies in Lymphoma, Large-Cell, Anaplastic by City of Hope Medical Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, Large-Cell, Anaplastic by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects and best dose of azacitidine in combination with belinostat and how well the combination works in treating patients with follicular helper T cell lymphoma (TFH) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). This phase I trial also tests the safety, side effects and best dose of pralatrexate in combination with belinostat and how well the combination works in treating patients with relapsed or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) with large cell transformation and cytotoxic phenotype. Azacitidine stops cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. It is a type of antimetabolite. Pralatrexate stops cells from using folic acid to make DNA. This may help keep cancer cells from growing and may kill them. Pralatrexate is a type of antimetabolite and a type of dihydrofolate reductase inhibitor. Belinostat blocks certain enzymes needed for cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. It is a type of histone deacetylase inhibitor, a type of antiangiogenesis agent, and a type of chemosensitizer. Giving azacitidine in combination with belinostat may be safe, tolerable, and/or effective in treating patients with relapsed/refractory (R/R) TFH. In additional, giving pralatrexate in combination with belinostat may be safe, tolerable, and/or effective in treating patients with R/R PTCL and CTCL with large cell transformation and cytotoxic phenotype.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the safety and feasibility of combining azacitidine with belinostat in R/R nodal TFH cell lymphoma. (Arm A) II. To evaluate the safety and feasibility of combining pralatrexate with belinostat in R/R PTCL and CTCL with large cell transformation. (Arm B)

SECONDARY OBJECTIVES:

I. To measure the clinical efficacy as measured by overall response rate (ORR), complete response (CR) rate, and time to next treatment (TTNT) of belinostat and azacitidine. (Arm A) II. Patient-reported outcomes as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health37 and Functional Assessment of Cancer Therapy (FACT)-Item GP5 scale. (Arm A) III. To measure the clinical efficacy as measured by ORR, CR rate, and TTNT of belinostat and pralatrexate. (Arm B) IV. Patient-reported outcomes as measured by the PROMIS Global Health37 and FACT-Item GP5 scale. (Arm B)

EXPLORATORY OBJECTIVES:

I. To measure survival outcomes by progression-free survival (PFS) and overall survival (OS) of belinostat and azacitidine. (Arm A) II. Examine the association between biomarkers (e.g., genomic proofing, minimal residual disease [MRD]) and clinical outcomes (ORR, PFS). (Arm A) III. To measure survival outcomes by PFS and OS of belinostat and pralatrexate. (Arm B) IV. Examine the association between biomarkers (e.g., genomic profiling, MRD) and clinical outcomes (ORR, PFS). (Arm B)

OUTLINE: Patients are assigned to 1 of 2 arms.

ARM A: Patients receive azacitidine subcutaneously (SC) on days 1-5 and belinostat intravenously (IV) over 30-45 minutes on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and fludeoxyglucose F-18 (FDG)-positron emission tomography (PET), and computed tomography (CT) or PET/CT throughout the study.

ARM B: Patients receive pralatrexate SC on days 8 and 15 and belinostat IV over 30-45 minutes on days 1-3 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and FDG-PET, and CT or PET/CT throughout the study.

After completion of study treatment, patients in Arm A are followed up at 30 days, every 3 months for up to 2 years, then for up to 5 years. Patients in Arm B are followed up at 30 days, every 3 months for up to one year from start of treatment, every 6 months for up to 2 years then every 5 years.

03

Conditions studied

  • Recurrent Anaplastic Large Cell Lymphoma
  • Recurrent Enteropathy-Associated T-Cell Lymphoma
  • Recurrent Follicular Helper T-Cell Lymphoma
  • Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
  • Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type
  • Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Hepatosplenic T-Cell Lymphoma
  • Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
  • Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
  • Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma
  • Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma
  • Refractory Anaplastic Large Cell Lymphoma
  • Refractory Enteropathy-Associated T-Cell Lymphoma
  • Refractory Follicular Helper T-Cell Lymphoma
  • Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
  • Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type
  • Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified
  • Refractory Hepatosplenic T-Cell Lymphoma
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
  • Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
  • Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma
  • Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign a written document
  • Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines
  • Age: ≥ 18 years
  • Have a performance status of 0-1 on the (ECOG) Scale (performance status [PS]) at time of enrollment. Patients with a performance status of 2 on the ECOG Scale due to lymphoma may be eligible with principal investigator (PI) approval
  • confirmed PTCL in the following subtypes below (by local review). Eligible histologies include:

    • Arm A

      • Histologically confirmed TFH cell lymphomas. Nodal TFH cell lymphomas encompasses three subtypes:

        • Angioimmunoblastic T-cell lymphoma (AITL)(World Health Organization [WHO]4R)/follicular helper T-cell lymphoma (TFH lymphoma), angioimmunoblastic type (ICC)/nodal TFH cell lymphoma, angioimmunoblastic-type (WHO5)
        • Nodal PTCL with TFH phenotype (nodal PTCL, TFH)(WHO4R)/TFH lymphoma, NOS (ICC)/nodal TFH cell lymphoma, not otherwise specified (NOS) (WHO5)
        • Follicular T-cell lymphoma (FTCL)(WHO4R)/TFH lymphoma, follicular type (ICC)/ nodal TFH cell lymphoma, follicular-type (WHO5)
    • Arm B

      • Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
      • Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)
      • Enteropathy-associated T-cell lymphoma (EATL)
      • Anaplastic large cell lymphoma (ALCL)
      • Hepatosplenic T-cell lymphoma
      • Cutaneous T-cell lymphoma (CTCL) with large cell transformation
      • Subcutaneous panniculitis-like T-cell lymphoma
      • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL)
      • Primary cutaneous gamma-delta T-cell lymphoma (PCGDTL)
  • Must have received at least one prior systemic therapy and have an indication for treatment

    • NOTE: For systemic ALCL, prior systemic therapy must have included brentuximab vedotin
  • , including at least 1 nodal site measuring ≥ 1.5cm or 1 extranodal site measuring 1.0 cm in longest dimension on CT or FDG-PET or marrow-only disease (disease only found on bone marrow )
  • > 12 weeks
  • Without bone marrow involvement: (ANC) ≥ 1,000/mm\^3

    • NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement
  • With bone marrow involvement: ANC ≥ 750/mm\^3

    • NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement
  • Without bone marrow involvement: ≥ 75,000/mm\^3

    • NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement
  • With bone marrow involvement: Platelets ≥ 50,000/mm\^3

    • NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement
  • ≥ 8g/dL

    • NOTE: Red blood cell transfusions are not permitted within 7 days of hemoglobin assessment unless cytopenia is secondary to disease involvement
  • Total ≤ 1.5 x (ULN)

    • NOTE: Patients with documented Gilbert's disease, documented liver or pancreatic involvement in lymphoma may be enrolled if total bilirubin ≤ 3.0 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 ULN
  • (AST) ≤ 3.0 x ULN OR ≤ 5 x ULN for patients with liver involvement by lymphoma
  • Alanine aminotransferase (ALT) ≤ 3.0 x ULN OR ≤ 5 x ULN for patients with liver involvement by lymphoma
  • Measured or calculated ≥ 60 mL/min ( [GFR] can also be used in place of creatinine clearance [CrCl])
  • If not receiving anticoagulants: (INR) OR prothrombin (PT) ≤ 1.5 x ULN
  • If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
  • If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN
  • If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
  • Women of (WOCBP): Negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential to use an effective method of or abstain from heterosexual intercourse for the course of the study and after completion of study treatment as described below separately for males and females

    • WOCBP must remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of ≤ 1% per year during the treatment period and for at least 1 month after the last dose of study treatment. Women must refrain from donating eggs during this same period

      • Examples of contraceptive methods with a failure rate of ≤ 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices
      • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient
      • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

      • With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 1 month after the last treatment. Men must refrain from donating sperm during this same period
      • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure
    • Childbearing potential defined as being post-menarcheal (women only), not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • Diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) within 7 days prior to cycle 1 day 1, for indications other than lymphoma symptom control. Patients who require lymphoma symptom control during screening may receive steroids in the following manner:

    • Up to 30 mg/day of prednisone or equivalent may be used for lymphoma symptom control during screening, including prior to finalization of staging (not included as part of pre-phase treatment). If glucocorticoid treatment is urgently required at higher doses for lymphoma symptom control prior to the start of study treatment, tumor assessments must be completed prior to initiation of > 30-100 mg/day of prednisone or equivalent. Prednisone > 30-100 mg/day or equivalent may be given for a maximum of 7 days as a pre-phase treatment. If patients exceed the allowed dosing of corticosteroids, patients may still be eligible for the study provided that baseline imaging is performed (or repeated) after completion of the course of higher dose of steroids. Allowed corticosteroid dosing resets from the point of imaging forward and patients who do not exceed the allowed corticosteroid dosing from the point of imaging until initiation of study treatment may enroll. Steroids at a dose less than the equivalent of 10 mg/day of prednisone and inhaled, nasal, and topical steroids are permitted. Adrenal replacement steroid doses > 10 mg daily prednisone equivalent in the absence of active disease are permitted. Treatment with a short course of steroids (\< 7 days) up to 7 days prior to cycle 1 day 1 is permitted

Exclusion criteria

Exclusion Criteria:

  • Patients who received prior therapy with belinostat or azacitidine (Arm A) or belinostat or pralatrexate (Arm B) without having had evidence of objective response (i.e. patients whose best response was stable disease or progressive disease)

    • Note: Patients who previously responded to any of these agents are eligible. Their last dose of either belinostat, azacitidine or pralatrexate must be > 14 days prior to day 1 of protocol therapy
  • Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy
  • Prior stem cell transplantation within 60 days of day 1 of protocol therapy
  • Major surgery within 4 weeks prior to the start of cycle 1, other than for diagnosis confirmation
  • UGT1A1 inhibitors within 14 days prior to day 1 of protocol therapy
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) which requires systemic treatment. Patients may proceed with screening during treatment for infection, but systemic treatment must be completed by cycle 1 day 1

    • If a patient has signs/symptoms suggestive of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the patient must have a negative molecular (e.g., polymerase chain reaction [PCR]) test or 2 negative antigen test results at least 24 hours apart. Patients who do not meet SARS-CoV-2 infection eligibility criteria must be screen-failed and may only be re-screened if the following have been met:

      • At least 10 days since first positive test result have passed in asymptomatic patients or at least 10 days since recovery, defined as resolution of fever without use of antipyretics and improvement in symptoms
  • Subjects with concurrent active (defined as hepatitis B virus surface antigen [HBsAg] positive and/or detectable hepatitis B virus [HBV] DNA) and/or virus (defined as anti-hepatitis C virus [HCV] antibody [Ab] positive and detectable HCV ribonucleic acid [RNA]) infection.

    • Hepatitis B and C screening tests are not required unless: (1) Known history of HBV and HCV infection or (2) As mandated by local health authority
  • Subjects with infection
  • Other active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial

    • Note: If such malignancies were treated with either belinostat, azacitidine, or pralatrexate the 14 day washout applies
  • Females only: Pregnant or breastfeeding
  • Known active central nervous system lymphoma
  • Participants who are receiving other investigational agents
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm A (azacitidine, belinostat)

    Patients receive azacitidine SC on days 1-5 and belinostat IV over 30-45 minutes on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and FDG-PET, and CT or PET/CT throughout the study.

    Drug: Azacitidine · Drug: Belinostat · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: FDG-Positron Emission Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Questionnaire Administration

  • Experimental
    Arm B (pralatrexate, belinostat)

    Patients receive pralatrexate SC on days 8 and 15 and belinostat IV over 30-45 minutes on days 1-3 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and FDG-PET, and CT or PET/CT throughout the study.

    Drug: Belinostat · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: FDG-Positron Emission Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Drug: Pralatrexate · Other: Questionnaire Administration

Interventions

  • Given SC

    Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • Given IV

    Also known as: Beleodaq, PXD 101, PXD-101, PXD101

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureFDG-Positron Emission Tomography

    Undergo FDG-PET

    Also known as: FDG, FDG-PET, FDG-PET Imaging

  • OtherFludeoxyglucose F-18

    Given FDG

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • Given SC

    Also known as: 10-propargyl-10-deazaaminopterin, Difolta, Folotyn, PDX

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicities (DLT) (Arm A)

    Observed toxicities will be summarized by type, severity, timing of onset, and attribution, and will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 6.0.

    Time frame: Prior to cycle 2 day 1 (cycle length = 28 days)

  2. Occurrence of DLT (Arm B)

    Observed toxicities will be summarized by type, severity, timing of onset, and attribution, and will be graded according to the CTCAE, version 6.0.

    Time frame: Prior to cycle 2 day 1 (cycle length = 21 days)

  3. Maximum tolerated dose (MTD) (Arm A)

    Will be defined as the highest dose of azacitidine tested in which at most 1 out of 6 DLT-evaluable patients treated at that dose experience a DLT. The MTD will be designated as the recommended phase 2 dose (RP2D), provided no additional safety concerns are identified.

    Time frame: During the first cycle of treatment (cycle length = 28 days)

  4. MTD (Arm B)

    Will be defined as the highest dose of pralatexate tested in which at most 1 out of 6 DLT-evaluable patients treated at that dose experience a DLT. The MTD will be designated as the RP2D, provided no additional safety concerns are identified.

    Time frame: During the first cycle of treatment (cycle length = 21 days)

Secondary outcomes

  1. Overall response rate (ORR) (Arm A)

    Will be estimated using simple binary proportions with corresponding two-sided 95% confidence intervals.

    Time frame: Up to 5 years

  2. ORR (Arm B)

    Will be estimated using simple binary proportions with corresponding two-sided 95% confidence intervals.

    Time frame: Up to 5 years

  3. Complete response (CR) rate (Arm A)

    Will be defined as the proportion of patients achieving a complete response according to standard response criteria. Will be estimated using simple binary proportions with corresponding two-sided 95% confidence intervals.

    Time frame: Up to 5 years

  4. CR rate (Arm B)

    Will be defined as the proportion of patients achieving a complete response according to standard response criteria. Will be estimated using simple binary proportions with corresponding two-sided 95% confidence intervals.

    Time frame: Up to 5 years

  5. Time to next treatment (TTNT) (Arm A)

    Continuous variables will be summarized using measures such as mean, standard deviation, median, range, and standard error, as appropriate. Categorical variables will be summarized using counts and percentages.

    Time frame: From the first dose of study treatment to initiation of subsequent anti-lymphoma therapy, assessed up to 5 years

  6. TTNT (Arm B)

    Continuous variables will be summarized using measures such as mean, standard deviation, median, range, and standard error, as appropriate. Categorical variables will be summarized using counts and percentages.

    Time frame: From the first dose of study treatment to initiation of subsequent anti-lymphoma therapy, assessed up to 5 years

  7. Patient reported outcomes (Arm A) - PROMIS Global Health37

    Will be measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health37. Will be summarized descriptively.

    Time frame: Up to 5 years

  8. Patient reported outcomes (Arm A) - FACT Item GP5

    Will be measured by the Functional Assessment of Cancer Therapy (FACT)-Item GP5 scale. Will be summarized descriptively.

    Time frame: Up to 5 years

  9. Patient reported outcomes (Arm B) - PROMIS Global Health37

    Will be measured by the PROMIS Global Health37. Will be summarized descriptively.

    Time frame: Up to 5 years

  10. Patient reported outcomes (Arm B) - FACT Item GP5

    Will be measured by the FACT-Item GP5 scale. Will be summarized descriptively.

    Time frame: Up to 5 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2029, 34 months later.

Of 31 phase 1 interventional studies under Lymphoma, Large-Cell, Anaplastic, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 9, 2026
StartEst.
Jan 3, 2027
Primary completionEst.
Nov 24, 2029
CompletionEst.
Nov 24, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added. City of Hope Medical Center is now Recruiting
Show site
  • City of Hope at Georgia - Atlanta · Newnan, United States
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site added. City of Hope Medical Center is now Recruiting
    Show site
    • City of Hope at Georgia - Atlanta · Newnan, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07691450
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jan 3, 2027 (estimated)
Primary completion
Nov 24, 2029 (estimated)
Completion
Nov 24, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Christina Poh
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Pralatrexate

Start the discussion